2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Mantle-Cell
8
Recurrence
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Interventions
Peripheral Blood Stem Cell Transplantation
26
Rituximab
20
Cyclophosphamide
18
fludarabine phosphate
17
Mycophenolic Acid
16
Tacrolimus
14
Cyclosporine
14
Whole-Body Irradiation
12
Filgrastim
11
Therapeutics
10
Psychiatric Rehabilitation
10
Flow Cytometry
10
Etoposide
10
Radiotherapy
8
Polymerase Chain Reaction
8
Methotrexate
8
Busulfan
8
Methylprednisolone
7
Antilymphocyte Serum
7
Cladribine
6
immunotoxin HA22
5
Lenalidomide
5
obinutuzumab
4
Vorinostat
4
Vemurafenib
4
Ondansetron
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
Dexamethasone
4
Cord Blood Stem Cell Transplantation
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Hairy Cell
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts